Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg in obesity and prediabetes
NCT05040971Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of semaglutide in prediabetes, sponsored by Novo Nordisk. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT05040971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040971.